REDWOOD CITY, CALIF – December 5, 2024 – Bone Health Technologies (BHT), a leading medical technology startup developing innovative non-pharmacological solutions to improve bone health and reduce fractures, today announced that pre-orders are now open for Osteoboost, the first and only FDA-cleared non-drug prescription treatment for postmenopausal women with osteopenia.
Osteoboost is a wearable medical device, worn low around the waist, that delivers targeted vibration therapy directly to the hips and spine – the areas most at risk of debilitating osteoporotic fractures. Its unique and patented combination of dynamically calibrated frequency and amplitude has been proven in a pivotal clinical trial to reduce the loss of spine bone density by 85% and bone strength by 83%.
Available now for a self-pay pre-order price of $995 (list price of $1,500), Osteoboost is expected to ship in the next 60-90 days to those who secure their device in advance. A special Founder’s Program offer to existing waitlist members has already sold out, and the company is accelerating production to meet the high demand.
“Osteoboost was developed as part of an overarching vision to provide people with a safe, convenient, and non-invasive solution to protect bone density and prevent fractures,” said Laura Yecies, CEO of Bone Health Technologies. “This is an exciting milestone for our team and the thousands of people who have patiently waited as we completed our clinical trial, successfully navigated the FDA De Novo clearance process, and begun man